Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Pictet Asset Management SA

Pictet Asset Management SA lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) by 46.6% during the second quarter, HoldingsChannel.com reports. The fund owned 121,867 shares of the biopharmaceutical company’s stock after selling 106,142 shares during the quarter. Pictet Asset Management SA’s holdings in Halozyme Therapeutics were worth $5,362,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its position in shares of Halozyme Therapeutics by 17.7% in the first quarter. Nisa Investment Advisors LLC now owns 6,791 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 1,020 shares in the last quarter. Mutual of America Capital Management LLC raised its position in Halozyme Therapeutics by 1.9% during the first quarter. Mutual of America Capital Management LLC now owns 128,384 shares of the biopharmaceutical company’s stock worth $5,120,000 after acquiring an additional 2,451 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Halozyme Therapeutics by 6.4% during the first quarter. Envestnet Asset Management Inc. now owns 64,678 shares of the biopharmaceutical company’s stock worth $2,579,000 after acquiring an additional 3,879 shares during the last quarter. Stephens Inc. AR lifted its holdings in shares of Halozyme Therapeutics by 14.6% in the first quarter. Stephens Inc. AR now owns 2,899 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 369 shares in the last quarter. Finally, Stephens Investment Management Group LLC grew its position in shares of Halozyme Therapeutics by 1.6% in the first quarter. Stephens Investment Management Group LLC now owns 1,294,937 shares of the biopharmaceutical company’s stock valued at $51,642,000 after purchasing an additional 20,258 shares during the last quarter. 91.72% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $54.13, for a total transaction of $541,300.00. Following the transaction, the senior vice president now directly owns 163,137 shares in the company, valued at approximately $8,830,605.81. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $54.13, for a total transaction of $541,300.00. Following the completion of the sale, the senior vice president now directly owns 163,137 shares in the company, valued at approximately $8,830,605.81. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $53.81, for a total value of $269,050.00. Following the completion of the transaction, the chief financial officer now directly owns 4,045 shares in the company, valued at $217,661.45. The disclosure for this sale can be found here. Insiders sold a total of 25,000 shares of company stock valued at $1,331,850 in the last 90 days. 2.30% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $52.94 on Friday. The business’s 50-day moving average price is $44.76 and its 200 day moving average price is $44.72. The company has a current ratio of 5.97, a quick ratio of 5.03 and a debt-to-equity ratio of 15.37. Halozyme Therapeutics, Inc. has a twelve month low of $31.36 and a twelve month high of $54.88. The company has a market capitalization of $7.16 billion, a PE ratio of 35.53, a price-to-earnings-growth ratio of 0.84 and a beta of 1.22.

Analysts Set New Price Targets

A number of research firms recently issued reports on HALO. SVB Leerink upped their target price on Halozyme Therapeutics from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Monday, November 14th. Morgan Stanley started coverage on Halozyme Therapeutics in a research note on Friday, September 9th. They set an “overweight” rating and a $50.00 price objective on the stock. StockNews.com began coverage on shares of Halozyme Therapeutics in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, JMP Securities raised their price target on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 9th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.57.

Halozyme Therapeutics Company Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Stories

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.